Ti D[Author] - Search Results

Year	Number of Results
2006	1
2007	1
2009	1
2011	1
2012	1
2013	4
2014	4
2015	8
2016	3
2017	2
2018	1
2019	2
2020	6
2021	2

1

Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma.

Tong C, Zhang Y, Liu Y, Ji X, Zhang W, Guo Y, Han X, Ti D, Dai H, Wang C, Yang Q, Liu W, Wang Y, Wu Z, Han W. Tong C, et al. Among authors: ti d. Blood. 2020 Oct 1;136(14):1632-1644. doi: 10.1182/blood.2020005278. Blood. 2020. PMID: 32556247 Free PMC article.

2

LPS-preconditioned mesenchymal stromal cells modify macrophage polarization for resolution of chronic inflammation via exosome-shuttled let-7b.

Ti D, Hao H, Tong C, Liu J, Dong L, Zheng J, Zhao Y, Liu H, Fu X, Han W. Ti D, et al. J Transl Med. 2015 Sep 19;13:308. doi: 10.1186/s12967-015-0642-6. J Transl Med. 2015. PMID: 26386558 Free PMC article.

3

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.

Dai H, Wu Z, Jia H, Tong C, Guo Y, Ti D, Han X, Liu Y, Zhang W, Wang C, Zhang Y, Chen M, Yang Q, Wang Y, Han W. Dai H, et al. Among authors: ti d. J Hematol Oncol. 2020 Apr 3;13(1):30. doi: 10.1186/s13045-020-00856-8. J Hematol Oncol. 2020. PMID: 32245502 Free PMC article. Clinical Trial.

4

Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation.

Jia H, Wang Z, Wang Y, Liu Y, Dai H, Tong C, Guo Y, Guo B, Ti D, Han X, Yang Q, Wu Z, Han W. Jia H, et al. Among authors: ti d. J Hematol Oncol. 2019 Jun 10;12(1):57. doi: 10.1186/s13045-019-0741-6. J Hematol Oncol. 2019. PMID: 31182121 Free PMC article.

5

PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity.

Wei J, Luo C, Wang Y, Guo Y, Dai H, Tong C, Ti D, Wu Z, Han W. Wei J, et al. Among authors: ti d. J Immunother Cancer. 2019 Aug 7;7(1):209. doi: 10.1186/s40425-019-0685-y. J Immunother Cancer. 2019. PMID: 31391096 Free PMC article.

6

Adaptive T cell immunotherapy in cancer.

Ti D, Bai M, Li X, Wei J, Chen D, Wu Z, Wang Y, Han W. Ti D, et al. Sci China Life Sci. 2020 Jul 23. doi: 10.1007/s11427-020-1713-9. Online ahead of print. Sci China Life Sci. 2020. PMID: 32712831 Review.

7

Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming.

Wang Y, Tong C, Dai H, Wu Z, Han X, Guo Y, Chen D, Wei J, Ti D, Liu Z, Mei Q, Li X, Dong L, Nie J, Zhang Y, Han W. Wang Y, et al. Among authors: ti d. Nat Commun. 2021 Jan 18;12(1):409. doi: 10.1038/s41467-020-20696-x. Nat Commun. 2021. PMID: 33462245 Free PMC article.

8

Mesenchymal stem cells-derived exosomal microRNAs contribute to wound inflammation.

Ti D, Hao H, Fu X, Han W. Ti D, et al. Sci China Life Sci. 2016 Dec;59(12):1305-1312. doi: 10.1007/s11427-016-0240-4. Epub 2016 Nov 18. Sci China Life Sci. 2016. PMID: 27864711 Review.

9

Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.

Ti D, Niu Y, Wu Z, Fu X, Han W. Ti D, et al. Sci China Life Sci. 2018 Nov;61(11):1320-1332. doi: 10.1007/s11427-018-9411-4. Epub 2018 Nov 7. Sci China Life Sci. 2018. PMID: 30414005 Review.

10

Efficiency and side effects of anti-CD38 CAR T cells in an adult patient with relapsed B-ALL after failure of bi-specific CD19/CD22 CAR T cell treatment.

Guo Y, Feng K, Tong C, Jia H, Liu Y, Wang Y, Ti D, Yang Q, Wu Z, Han W. Guo Y, et al. Among authors: ti d. Cell Mol Immunol. 2020 Apr;17(4):430-432. doi: 10.1038/s41423-019-0355-5. Epub 2020 Jan 3. Cell Mol Immunol. 2020. PMID: 31900459 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results